Oruka Therapeutics
ORKA
24 hedge funds and large institutions have $4.17M invested in Oruka Therapeutics in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
60% more capital invested
Capital invested by funds: $2.6M → $4.17M (+$1.57M)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
9% more funds holding
Funds holding: 22 → 24 (+2)
0.31% more ownership
Funds ownership: 0.66% → 0.97% (+0.31%)
92% less call options, than puts
Call options by funds: $328K | Put options by funds: $3.96M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$537K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$310K |
| 3 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$119K |
| 4 |
Millennium Management
New York
|
+$113K |
| 5 |
B
Bailard
Foster City,
California
|
+$82.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$55K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$22.9K |
| 3 |
BlackRock
New York
|
-$13.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$11K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$6.13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| – | -$2K | -56 | Closed |
|
27
Wells Fargo
San Francisco,
California
| – | +$28 | +1 | +14% |
|
ORKA Hedge Fund Activity: Q2 2022 in Review
24 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2022, worth a combined $4.17M — up 60% from $2.6M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ORKA positions and 5 closed out — a net gain of 2 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $537K. The largest seller was Virtu Financial, exiting entirely with an estimated $55K sold.
- 24 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2022, up from 22 in Q1 2022.
- Funds reported $4.17M of Oruka Therapeutics stock for Q2 2022, up 60% quarter-over-quarter.
- 7 funds opened new Oruka Therapeutics positions in Q2 2022 and 5 closed out, a net change of +2 holders.
- The largest Oruka Therapeutics buyer in Q2 2022 was Susquehanna International Group, an estimated $537K added.
- The largest Oruka Therapeutics seller in Q2 2022 was Virtu Financial, an estimated $55K sold.
Based on aggregated 13F filings for Q2 2022.